Intrinsiqq
Hyloris Pharmaceuticals SA logo

Hyloris Pharmaceuticals SA Quality Score

HYL.XBRU

Compare
Quality46

Valuation is the primary weakness (avg 0/100). Business quality is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-18.0x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-16.3x

Negative FCF, no valuation support

Revenue Growth
100/100
100.1%

Above 10% CAGR, strong compounder

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
60/100
1.3%

Mild dilution under 2%

Margin Trend
100/100
+1184.2pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-€12M

Net cash position, no leverage concern

2022
€43.0M
€885000
2023
€30.0M
€2.00M
2024
€24.0M
€2.00M
2025
€14.0M
€2.00M
CashDebt
Return on Capital
0/100
-19.6%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Hyloris Pharmaceuticals SA (HYL.XBRU) quality: score, margins and returns

Hyloris Pharmaceuticals SA (HYL.XBRU) scores 46/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 6 metrics each scored 0 to 100, on -94.5% operating margins and -19.6% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Hyloris Pharmaceuticals SA (HYL.XBRU) a high-quality business?+

Hyloris Pharmaceuticals SA scores 46 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a -94.5% operating margin and a -19.6% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Hyloris Pharmaceuticals SA's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from HYL.XBRU's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Hyloris Pharmaceuticals SA scores well and where it falls behind.

What is Hyloris Pharmaceuticals SA's return on invested capital (ROIC)?+

Hyloris Pharmaceuticals SA earns about -19.6% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to HYL.XBRU's margins and growth on this scorecard to judge durability.

How profitable is Hyloris Pharmaceuticals SA?+

Hyloris Pharmaceuticals SA runs an operating margin of about -94.5% and a net margin of about -87.9%. Revenue has grown at roughly 23.5% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

How the market compares: US profitability statistics

Peers

Biotechnology · Pick stocks to compare with HYL.XBRU

CompareIntrinsic value
ALEMS.XBRUEuropean Medical Solutions S.A.
€3.50+2.34%76
IMRNImmuron Ltd. Sponsored ADR
$0.90+5.86%40
BIG1.XETRBio-Gate AG
€2.06+3.00%36
ACOU.XSTOAcousort AB
€0.22+0.45%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
ABLD.XPARABL Diagnostics S.A.
€2.34+0.00%46
EVAXEvaxion A/S American
$2.26+11.33%10
ACARIX.XSTOAcarix AB
€0.01+0.00%40

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing HYL.XBRU

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.